Cerebral rituximab uptake in multiple sclerosis: A 89Zr-immunoPET pilot study
2017 ◽
Vol 24
(4)
◽
pp. 543-545
◽
Keyword(s):
Previous studies have demonstrated that the chimeric monoclonal antibody rituximab significantly reduces clinical and radiological disease activity in relapsing-remitting multiple sclerosis as early as 4 weeks after the first administration. The exact mechanisms leading to this rapid effect have not yet been clarified. The aim of this positron emission tomography study was to assess central nervous system penetration as a possible explanation, using zirconium-89-labelled rituximab. No evidence was found for cerebral penetration of [89Zr]rituximab.
2006 ◽
Vol 245
(1-2)
◽
pp. 103-109
◽
2018 ◽
Vol 24
(7)
◽
pp. 1002-1004
◽
2018 ◽
Vol 25
(26)
◽
pp. 3096-3104
◽
2019 ◽
Vol 116
(23)
◽
pp. 11402-11407
◽
1999 ◽
Vol 162
(4)
◽
pp. 1322-1328
◽
2002 ◽
Vol 133
(1-2)
◽
pp. 184-192
◽